Abstract 4946: TOS-358, a first-in-class covalent PI3Kα inhibitor, demonstrates superior efficacy and does not induce significant hyperglycemia at efficacious doses in multiple animal models
Year: 2023
Type: conference-abstract
Source: Cancer Research
Authors: John R. MacDougall, John Bradley, Raymond Mak, Neil Dhawan, Wei Chen
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4362594928